AstraZeneca Gets Crowded by Merck, Bristol on Lung CancerBy
CEO says competing products cleared `far faster' than expected
Lung cancer drug to be submitted in first half of next year
AstraZeneca Plc may shelve a plan for seeking accelerated approval of a key experimental cancer drug because Bristol-Myers Squibb Co. and Merck & Co. moved faster to crowd the U.S. market for lung tumors.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.